Primate testing of TGN1412: right target, wrong cell
- 3 September 2010
- journal article
- editorial
- Published by Wiley in British Journal of Pharmacology
- Vol. 161 (3) , 509-511
Abstract
The failure of toxicity studies in non‐human primates to predict the cytokine release syndrome during a first‐in‐man study of the CD28‐specific monoclonal antibody TGN1412 has remained unexplained so far. In this issue of the BJP, work from the NIBSC first identifies the effector memory subset of human T‐lymphocytes as the most likely source of the pro‐inflammatory cytokines released during the study, and goes on to show that in cynomolgus monkeys, this subset lacks CD28, the target molecule of TGN1412. We discuss the implications for the TGN1412 catastrophe and for preclinical evaluation of biologicals in animal models in general.Keywords
This publication has 7 references indexed in Scilit:
- Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T‐cellsBritish Journal of Pharmacology, 2010
- Rapid Regulatory T-Cell Response Prevents Cytokine Storm in CD28 Superagonist Treated MicePLOS ONE, 2009
- Manipulation of Regulatory T‐Cell Number and Function with CD28‐Specific Monoclonal Antibodies2007
- Lessons from TGN1412The Lancet, 2006
- Establishing risk of human experimentation with drugs: lessons from TGN1412The Lancet, 2006
- Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412New England Journal of Medicine, 2006
- Development and Homeostasis of T Cell Memory in Rhesus MacaqueThe Journal of Immunology, 2002